Patents by Inventor Michael George Mulkerrin

Michael George Mulkerrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7741072
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Publication number: 20080138338
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Application
    Filed: October 12, 2007
    Publication date: June 12, 2008
    Applicant: Genentech, Inc.
    Inventors: ESOHE EKINADUESE IDUSOGIE, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 7364731
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: April 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 7297775
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Publication number: 20030158389
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Application
    Filed: November 12, 2002
    Publication date: August 21, 2003
    Applicant: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 6538124
    Abstract: Isolated nucleic acid, vectors and host cells encoding antibody or immunoadhesin variants, as well as a process for producing the variants. The variants comprise a human IgG Fc region with amino acid substitution(s) therein, and display altered C1q binding function.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: March 25, 2003
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 6528624
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: March 4, 2003
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 6242195
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: June 5, 2001
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Michael George Mulkerrin, Leonard G. Presta, Robert Laird Shields
  • Patent number: 6194551
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: February 27, 2001
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin